5 completed, 5 recruiting, 2 active not recruiting, 2 terminated. 10 Phase 2, 3 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Recruiting 2, Terminated 2, Active not recruiting 1 |
| Not applicable | 3 | Recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Nonseminomatous germ cell tumor: new trials by email Literature Review of Nonseminomatous germ cell tumor trials Research Report on Nonseminomatous germ cell tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: - Urothelial Carcinoma, Renal Cancer | Not applicable | Recruiting | Institut Claudius Regaud | 450 | 2025-07-23 | 2026-06-15 |
| High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors High-dose chemotherapy (TI- 2 cycles, CE- 3 cycles ) - Germ Cell Tumor | Phase 2 | Recruiting | N.N. Petrov National Medical Research Center of Oncology | 25 | 2024-03-01 | 2025-08-03 |
| Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer Robot-assisted ICG-guided sentinel lymph node biopsy - Germ Cell Tumor, Seminoma | Not applicable | Recruiting | Heinrich-Heine University, Duesseldorf | 44 | 2023-09-06 | 2025-09-15 |
| Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors BEP Protocol, Dose-dense regimen, Early tumor resection or HD-CT - Non-Seminomatous Germ Cell Tumor | Not applicable | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 150 | 2023-05-05 | 2025-05-08 |
| CD30 CAR for CD30+ NSGCT ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 2 | 2022-12-09 | 2026-07-07 |
| A Phase II Trial of Cabozantinib With Patients With Refractory GCTs Cabozantinib - Germ Cell Tumor, Seminoma | Phase 2 | Completed | Jennifer King | 50 | 2021-06-10 | 2026-10-16 |
| Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT Etoposide - Germ Cell Tumor, Non-seminomatous Germ Cell Tumor | Phase 2 | Recruiting | Nabil Adra | 64 | 2021-03-03 | 2026-05-08 |
| Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors Durvalumab, Tremelimumab - Germ Cell Tumor, Nonseminomatous Germ Cell Tumor | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2017-05-15 | 2026-09-18 |
| Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors Brentuximab Vedotin - Germ Cell Tumors, Testis Cancer | Phase 2 | Terminated | Nabil Adra | 18 | 2016-03-09 | 2019-12-10 |
| Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors Pembrolizumab - Germ Cell Neoplasms, Testicular Neoplasms | Phase 2 | Terminated | Nasser Hanna, M.D. | 12 | 2016-01-01 | 2022-07-11 |
| Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors paclitaxel, ifosfamide, cisplatin - Germ Cell Tumor, Teratoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 420 | 2015-08-06 | 2026-06-16 |
| Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy K5-RGD PET, FDG - Non-seminomatous Germ Cell Tumors, Metastasis | Phase 2 | Completed | Centre Francois Baclesse | 16 | 2014-12-01 | 2020-07-09 |
| A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors Cabazitaxel - Non-seminomatous Germ-cell Tumors | Phase 2 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 34 | 2014-07-23 | 2026-04-06 |
| Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Dabrafenib, Trametinib - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 206 | 2014-03-12 | 2023-08-21 |
Neoplasms, Germ Cell and Embryonal (9) · Seminoma (5) · Germinoma (3) · Choriocarcinoma (2) · Endodermal Sinus Tumor (2) · Neoplasms (2) · Teratoma (2) · Testicular Neoplasms (2) · Biliary Tract Neoplasms (1) · Carcinoma, Embryonal (1) · Carcinoma, Transitional Cell (1) · Dysgerminoma (1) · Gastrointestinal Stromal Tumors (1) · Genital Neoplasms, Female (1)
Neoplasms by Histologic Type (11) · Neoplasms (10) · Urogenital Diseases (5) · Carcinoma (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Genital Diseases (3) · Male Urogenital Diseases (3) · Urogenital Neoplasms (3) · Adenocarcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Genital Diseases, Female (2)
Drug Therapy (2) · Etoposide (2) · BEP protocol (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Cisplatin (1) · Cyclophosphamide (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Paclitaxel (1) · cabazitaxel (1) · cabozantinib (1) · dabrafenib (1) · durvalumab (1) · etoposide phosphate (1)
Gustave Roussy, Cancer Campus, Grand Paris (2) · Nabil Adra (2) · Alliance for Clinical Trials in Oncology (1) · Centre Francois Baclesse (1) · Heinrich-Heine University, Duesseldorf (1) · Institut Claudius Regaud (1) · Jennifer King (1) · Memorial Sloan Kettering Cancer Center (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Nasser Hanna, M.D. (1) · Novartis Pharmaceuticals (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (8) · France (6) · Germany (3) · Belgium (2) · Denmark (2) · Italy (2) · Netherlands (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · Ireland (1) · Japan (1) · Norway (1) · Russia (1)
Aleksei M Belyaev, MD,DSc,Prof. (1) · Costantine Albany, MD (1) · Darren Feldman, MD (1) · Jennifer King, MD (1) · Matthew I Milowsky (1) · Nabil Adra, MD (1) · Nasser Hanna, M.D. (1) · Samuel Funt, MD (1) · Tatyana Yu Semiglazova, MD,DSc,Prof. (1)
PMID 25092772, PMID 29045540, PMID 29072975, PMID 30563754, PMID 32818466, PMID 34838156, PMID 36108341, PMID 36737276, PMID 37059834, PMID 37219859, PMID 37934000, PMID 39028926
2023 (1), U10CA180821 (1)